Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñ¼Ò¼¼Æ÷¼º Æó¾Ï¿¡¼­ 3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼± Ä¡·á¼ºÀû Clinical Experience of Three Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1998³â 16±Ç 3È£ p.265 ~ 274
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖÀº°æ/Eun Kyung Choi À̺´¿ë/°­¿øö/³ë¿µÁÖ/Á¤¿ø±Ô/¾È½Âµµ/±èÁ¾ÈÆ/ÀåÇý¼÷/Byong Yong Yi/One Chul Kang/Young Ju Nho/Weon Kuu Chung/Seung Do Ahn/Jong Hoon Kim/Hyesook Chang

Abstract

¸ñ Àû : ºñ¼Ò¼¼Æ÷¼º Æó¾Ï¿¡¼­ »õ·Î¿î Ä¡·á¹æ¹ýÀ¸·Î ´ëµÎµÇ°í ÀÖ´Â 3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼±
Ä¡·á (Three dimensional conformal radiotherapy, 3DCRT)ÀÇ ÀÓ»óÀû¿ë °¡´É¼º°ú ±âÁ¸ÀÇ Ä¡
·á¹ý¿¡ ºñÇÑ ÀåÁ¡À» ã°íÀÚ 1994³âºÎÅÍ ÀüÇâÀû ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù. º» ¿¬±¸´Â 1) °¡Àå È¿°ú
ÀûÀÎ 3Â÷¿ø ÀÔüÁ¶Çü Ä¡·á ¹æ¹ýÀÇ °³¹ß, 2) °¡´ÉÇÑ ÃÑ Ä¡·á ¼±·®Áõ°¡, 3) ¼±·® Áõ°¡¿¡ µû¸¥
¹æ»ç¼± Æó·Å ¹ß»ý À§Ç豺 ¿¹Ãø, 4) ¼±·®Áõ°¡¿¡ µû¸¥ ±¹¼Ò°üÇØ ¹× »ýÁ¸À² Çâ»óÀ» ¸ñÀûÀ¸·Î
ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1996³â 12¿ù±îÁö ¼ö¼úÀÌ ºÒ°¡´ÉÇÏ´Ù°í ÆÇÁ¤µÈ 95¸íÀÇ È¯ÀÚ(stage ¥°; 4¸í,
stage ¥±; 1¸í, stage ¥²a; 14¸í, stage ¥²b, 76¸í)¿¡ ´ëÇÏ¿© 3Â÷¿ø ÀÔüÁ¶Çü Ä¡·á¸¦ ½ÃÇàÇÏ¿´
´Ù. 3Â÷¿ø ÀÔüÁ¶Çü Ä¡·á¸¦ À§ÇÏ¿© °íÁ¤±â±¸¸¦ ÀÌ¿ëÇÏ¿© ¾Ó¿ÍÀ§ ȤÀº º¹¿ÍÀ§ »óÅ·ΠÀÚ¼¼¸¦
°íÁ¤ÇÑ ´ÙÀ½ CT-simulator¸¦ ÀÌ¿ëÇÏ¿© 5 mm°£°ÝÀ¸·Î CT ¿µ»óÀ» ¾ò°í GTV (Gross
Tumor Volume), CTV (Clinical Target Volume), PTV (Planning Target Volume)¸¦ Á¤ÇÑ
ÈÄ 3Â÷¿ø Ä¡·á°èȹ¿ë ÄÄÇ»Å͸¦ ÀÌ¿ëÇÏ¿© Ä¡·á°èȹÀ» ¼¼¿ü´Ù. ¹æ»ç¼± Ä¡·á´Â À°¾ÈÀû Á¾¾ç°ú
¸²ÇÁÀýÀ» Æ÷ÇÔÇÏ´Â ºÎÀ§¿¡ 36-40 Gy¸¦ AP-PA·Î Ä¡·áÇÑ ÈÄ 25-34 GyÀÇ 3Â÷¿ø ÀÔüÁ¶Çü
Ä¡·á¸¦ Ãß°¡Á¶»çÇÏ¿© ÃÑ 65-70 Gy¸¦ ½ÃÇàÇÏ¿´´Ù. ÀÌÁß 78¸í (82.1%)ÀÇ È¯ÀÚ´Â 2ȸÀÇ MVP
(Mitomycin C, Vinblastine, Cisplatin) º¹ÇÕÇ׾Ͽä¹ýÀ» µ¿½Ã¿¡ ½ÃÇàÇÏ¿´´Ù. 3Â÷¿ø ÀÔüÁ¶Çü
Ä¡·á °èȹÀº 1) Ç¥Àû ºÎÀ§ÀÇ 3Â÷¿ø ¼±·®ºÐÆ÷, 2) DVH (Dose Volume Histogram), 3)
NTCP (Normal Tissue Complication Probability)¸¦ ÀÌ¿ëÇÏ¿© ±âÁ¸ÀÇ 2Â÷¿ø Åë»ó Ä¡·á °èȹ
°ú ºñ±³ÇÏ¿´´Ù.
°á °ú : 78¸íÀÇ È¯ÀÚ¿¡¼­´Â 4-8 Á¶»ç¿µ¿ªÀ» ÀÌ¿ëÇÏ´Â ºñµ¿ÀÏ Æò¸é ÀÔüÁ¶Çü Ä¡·á
(Noncoplanar 3DCRT) ¹æ¹ýÀ» »ç¿ëÇÏ¿´À¸¸ç 17¸í¿¡¼­´Â Coplanar segmented 3DCRT ¹æ¹ý
À¸·Î Ä¡·áÇÏ¿´´Ù. °ÅÀÇ ¸ðµç ȯÀÚ¿¡¼­ Ç¥ÀûºÎÀ§¿¡ 100%ÀÇ ¼±·® Á¶»ç°¡ °¡´ÉÇÏ¿´À¸¸ç ½ÉÀå
¿¡ ´ëÇÑ DVH ºÐ¼®°á°ú ÁÂÆóÇÏ¿± ºÎÀ§ Á¾¾ç Ä¡·á½Ã¿¡´Â ƯÈ÷ 3Â÷¿ø ÀÔüÁ¶Çü Ä¡·á°¡ ½ÉÀå
¼±·®À» ÁÙ¿©ÁÜÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. 3Â÷¿ø ÀÔüÁ¶Çü Ä¡·á¿¡ ÀÇÇÑ µ¿ÃøÆóÀÇ NTCP Æò±Õ°ªÀº 0.26
(0.17-0.43)À¸·Î 2Â÷¿ø Åë»ó Ä¡·áÀÇ NTCP Æò±Õ°ª 0.38 (0.27-0.66)¿¡ ºñÇÏ¿© ºÎÀÛ¿ëÀÌ »ý±æ
È®·üÀÌ 32% ÁÙ¾îµé¾ú´Ù. Ä¡·á °á°ú´Â 26%(25/95)ÀÇ È¯ÀÚ¿¡¼­ ¿ÏÀü°üÇظ¦ º¸¿´À¸¸ç 53%
(50/95)¿¡¼­´Â ºÎºÐ°üÇظ¦ º¸¿© Àüü 79%ÀÇ È¯ÀÚ¿¡¼­ ºÎºÐ°üÇØ ÀÌ»óÀÇ ¹ÝÀÀÀ» º¸¿´´Ù. 1±â
¿Í 2±â ȯÀÚ 5¸íÀ» Á¦¿ÜÇÑ 3±â ȯÀÚ 90¸íÀÇ 1³â°ú 2³â »ýÁ¸À²Àº 62.6%¿Í 35.2%·Î °°Àº ±â
°£¿¡ 2Â÷¿ø Åë»óÄ¡·á·Î Ä¡·á¹ÞÀº ȯÀÚÀÇ 1³â°ú 2³â »ýÁ¸À² 51.9%¿Í 26.8%¿¡ ºñÇÏ¿© ´Ù¼Ò
Áõ°¡ µÇ¾úÀ¸³ª Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö´Â ¾Ê¾Ò´Ù. Ä¡·áÈÄ 19¸í (Grade 1:8, Grade
2:11)ÀÇ È¯ÀÚ¿¡¼­ ¹æ»ç¼± Æó·ÅÀÌ ¹ß»ýÇÏ¿´À¸³ª steroid Ä¡·áÈÄ ¸ðµÎ È£ÀüµÇ¾úÀ¸¸ç Ä¡·á ÈÄ
¹ß»ýÇÏ´Â ¹æ»ç¼± Æó·ÅÀ» ¿¹ÃøÇÒ ¼ö ÀÖ´Â °¡Àå ÁÁÀº ÁöÇ¥´Â µ¿ÃøÆó¿¡ ´ëÇÑ NTCP °ªÀ̾ú´Ù
(35% vs 22%).
°á ·Ð : ÀÌ»óÀÇ °á°ú Æó¾Ï¿¡ ´ëÇÑ 3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼± Ä¡·á´Â ±âÁ¸ÀÇ Ä¡·á¹ý¿¡ ºñÇÏ¿©
ºÎÀÛ¿ëÀÇ Áõ°¡ ¾øÀÌ ÃÑ ¹æ»ç¼±·®À» Áõ°¡½Ãų ¼ö ÀÖ´Â ÁÁÀº ¹æ¹ýÀ¸·Î »ý°¢µÇ¸ç ¹æ»ç¼± Æó·Å
ÀÇ ¿¹ÃøÀÎÀڷδ µ¿ÃøÆó¿¡ ´ëÇÑ NTCP °ªÀÌ ¸Å¿ì À¯¿ëÇÑ °ÍÀ¸·Î º¸¿©Áø´Ù. ÇâÈÄ NTCP °ª
¿¡ µû¸¥ ¼±·®Áõ°¡ ¿¬±¸¿Í ÀÌ¿¡ µû¸¥ »ýÁ¸À²ÀÇ Áõ°¡¿¡ ´ëÇÑ ¿¬±¸°¡ ´õ ÁøÇàµÇ¾î¾ß ÇÒ °ÍÀÌ
´Ù.

Purpose : This Prospective study has been conducted to assess the value of three
dimensional conformal radiation therapy (3DCRT) for lung cancer and to determine its
potential advantage over current treatment approaches. Specific aims of this study were
to 1) find the most ideal 3DCRT technique 2) establish the maximum tolerance dose
that can be delivered with 3DCRT and 3) identify Patients at risk for development of
radiation pneumonitis
Materials and Methods : Beginning in Nov. 1994, 95 patients with inoperable
non-small cell lung cancer (stage ¥°; 4, stage ¥±; 1, stage ¥²a; 14, stage ¥²b; 76) were
entered onto this 3D conformal trial. Areas of known disease and elective nodal areas
were initially treated to 45 Gy and then using 3DCRT technique 65 to 70 Gy of total
dose were delivered to the gloss disease. Sixty nine patients received 65 Gy of total
dose and 26 received 70 Gy. Seventy eight patients (82 1%) also received concurrent
MVP chemotherapy. 3DCRT plans were compared with 2D plans to assess the adequacy
of dose delivery to target volume, dose volume histograms for normal tissue, and normal
tissue complication probabilities (NTCP).
Results : Most of plans (78/95) were composed of non-coplanar multiple (4-8) fields.
Coplanar segmented conformal therapy was used in 17 pateints, choosing the proper
gantry an91e which minimize normal lung exposure in each segment. 3DCRT gave the
full dose to nearly 100% of the gross disease target volume in all patients. The mean
NTCP for ipsilateral lung with 30CRT (range; 0.17-0.43) was 68% of the mean NTCP
with 2D treatment planning (range; 0.27-0.66). DVH analysis for heart showed that
irradiated volume of heart could be significantly reduced by non-coplanar 3D approach
especially in the case of left lower lobe lesion. Of 95 patients evaluable for response, 75
(79%). showed major response including 25 (26%) with complete responses and 50
(53%) with partial responses. One and two years overall survivals of stage ¥² patients
were 62.6% and 35.2% respectively. Twenty percent (19/95) of patients had pneumonitis;
Eight patients had grade 1 pneumonitis and 11 other patients had grade 2. Comparison
of the average of NTCP for lung showed a significant difference between patients with
and without radiation pneumonitis. Average NTCP for patients without complication was
62% of those with complications.
Conclusion : This study showed that non-coplanar multiple fields (4-8) may be one of
the ideal plans for 3DCRT for lung cancer. It also suggested that 3DCRT may provide
superior delivery of high dose radiation with reduced risk to normal tissue and that
NTCP can be used as a guideline for the dose escalation.

Å°¿öµå

3D conformal RT; Non-small cell lung cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS